Effect of challenge with vasopressin (AVP) | Constant flow | AVP | 0.025 μM | | | 3 |

| Diluent | 0 | | | 5 |

| Constant flow | AVP | 0.05 μM | | | 6 |

| | Diluent | 0 | | | 7 |

| Constant flow | AVP | 0.1 μM | | | 5 |

| | Diluent | 0 μg/ml | | | 5 |

Effect of ET challenge with constant flow | Constant flow | PA | 2.0 μg/ml | | | 7 |

| ET | 1.0 μg/ml | | | 7 |

| Constant flow | PA | 4.0 μg/ml | | | 7 |

| | ET | 2.0 μg/ml | | | 6 |

Effect of ET challenge with constant pressure | Constant pressure | PA | 1.0 μg/ml | | | 9 |

| ET | 0.5 μg/ml | | | 9 |

| Constant pressure | PA | 2.0 μg/ml | | | 6 |

| | ET | 1.0 μg/ml | | | 6 |

Effect of raxibacumab treatment with ET challenge | Constant flow | ET | 1.0 μg/ml | Raxibacumab | 10×^{b} | 8 |

| ET | 1.0 μg/ml | Control | 0 | 6 |

| Constant flow | ET | 1.0 μg/ml | Raxibacumab | 50× | 3 |

| | ET | 1.0 μg/ml | Control | 0 | 3 |

Effect of adefovir treatment with ET challenge | Constant flow | ET | 1.0 μg/ml | Adefovir | 20 μM | 7 |

| ET | 1.0 μg/ml | Control | 0 | 5 |

| Constant flow | ET | 2.0 μg/ml | Adefovir | 20 μM | 4 |

| | ET | 2.0 μg/ml | Control | 0 | 4 |